Skip to content
Biodatica
Start free

Janssen Research & Development, LLC

Duarte, California

OncologyvaccinePhase IIIListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Long-term Extension Study of PCI-32765 (Ibrutinib)

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

96no change

Momentum 96 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    May 30, 2024

    Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

    ClinicalTrials.gov · NCT05963074 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    May 18, 2023

    Carcinoma, Non-Small-Cell Lung · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

    ClinicalTrials.gov · NCT05908734 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Jul 21, 2022

    Myeloproliferative Neoplasms · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

    ClinicalTrials.gov · NCT05444530 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Jul 28, 2021

    Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

    ClinicalTrials.gov · NCT04876092 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Apr 3, 2019

    Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

    ClinicalTrials.gov · NCT03900598 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Jul 20, 2016

    Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell · WITHDRAWN · sponsor: Janssen Research & Development, LLC · Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

    ClinicalTrials.gov · NCT02743546 (opens the source filing in a new tab)

  7. Trial

    PHASE2 registered

    Sep 2, 2015

    Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular · TERMINATED · sponsor: Janssen Research & Development, LLC · An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

    ClinicalTrials.gov · NCT02413489 (opens the source filing in a new tab)

  8. Trial

    PHASE3 registered

    Sep 9, 2013

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease · RECRUITING · sponsor: Janssen Research & Development, LLC · A Long-term Extension Study of PCI-32765 (Ibrutinib)

    ClinicalTrials.gov · NCT01804686 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources